{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:43:56Z","timestamp":1781617436159,"version":"3.54.5"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.neuropharm.2025.110656","type":"journal-article","created":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T14:18:37Z","timestamp":1756045117000},"page":"110656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Early treatment with vildagliptin and linagliptin reduces social fear and prevents the onset of comorbid depression in a mouse model of social anxiety disorder"],"prefix":"10.1016","volume":"279","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7187-3181","authenticated-orcid":false,"given":"Iulia","family":"Zoicas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8096-3987","authenticated-orcid":false,"given":"Johannes","family":"Kornhuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110656_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176525","article-title":"Liraglutide and Naringenin relieve depressive symptoms in mice by enhancing neurogenesis and reducing inflammation","volume":"971","author":"Abdelkawy","year":"2024","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110656_bib2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrn.2017.45","article-title":"Adult hippocampal neurogenesis and cognitive flexibility - linking memory and mood","volume":"18","author":"Anacker","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110656_bib3","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s11011-015-9656-2","article-title":"Sitagliptin protects proliferation of neural progenitor cells in diabetic mice","volume":"30","author":"Bachor","year":"2015","journal-title":"Metab. Brain Dis."},{"issue":"23","key":"10.1016\/j.neuropharm.2025.110656_bib4","article-title":"Saxagliptin: a potential doping agent? A randomized, double-blinded, placebo-controlled, and crossover pilot study in young active men","volume":"10","author":"Bourdillon","year":"2022","journal-title":"Phys. Rep."},{"issue":"16","key":"10.1016\/j.neuropharm.2025.110656_bib5","doi-asserted-by":"crossref","first-page":"8685","DOI":"10.3390\/ijms25168685","article-title":"Brain region-specific expression levels of synuclein genes in an acid sphingomyelinase knockout mouse model: correlation with depression-\/anxiety-like behavior and locomotor activity in the absence of genotypic variation","volume":"25","author":"Brazdis","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110656_bib6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.psyneuen.2015.01.007","article-title":"DPP4-deficient congenic rats display blunted stress, improved fear extinction and increased central NPY","volume":"53","author":"Canneva","year":"2015","journal-title":"Psychoneuroendocrinology"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110656_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/gpsych-2019-100076","article-title":"More anxious than depressed: prevalence and correlates in a 15-nation study of anxiety disorders in people with type 2 diabetes mellitus","volume":"32","author":"Chaturvedi","year":"2019","journal-title":"Gen. Psychiatry"},{"issue":"20","key":"10.1016\/j.neuropharm.2025.110656_bib8","doi-asserted-by":"crossref","first-page":"7777","DOI":"10.3390\/ijms21207777","article-title":"Neurotrophic factor BDNF, physiological functions and therapeutic potential in depression, neurodegeneration and brain cancer","volume":"21","author":"Colucci-D'Amato","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110656_bib9","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1021\/cn200127e","article-title":"Neuropeptide Y protects rat cortical neurons against \u03b2-amyloid toxicity and re-establishes synthesis and release of nerve growth factor","volume":"3","author":"Croce","year":"2012","journal-title":"ACS Chem. Neurosci."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110656_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyae062","article-title":"Exploring the anxiolytic potential of NPY by a dipeptidyl peptidase-IV inhibitor in an animal model of PTSD","volume":"27","author":"Dahan","year":"2024","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110656_bib11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11481-024-10142-w","article-title":"Semaglutide attenuates anxious and depressive-like behaviors and reverses the cognitive impairment in a type 2 diabetes mellitus mouse model via the microbiota-gut-brain axis","volume":"19","author":"de Paiva","year":"2024","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110656_bib12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hipo.20765","article-title":"Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis","volume":"21","author":"Decressac","year":"2011","journal-title":"Hippocampus"},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110656_bib13","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection","volume":"9","author":"During","year":"2003","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110656_bib14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbr.2006.04.003","article-title":"Behavioral characterization of CD26 deficient mice in animal tests of anxiety and antidepressant-like activity","volume":"171","author":"El Yacoubi","year":"2006","journal-title":"Behav. Brain Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110656_bib15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00213-009-1610-8","article-title":"Fear-reducing effects of intra-amygdala neuropeptide Y infusion in animal models of conditioned fear: an NPY Y1 receptor independent effect","volume":"206","author":"Fendt","year":"2009","journal-title":"Psychopharmacology (Berl)."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110656_bib16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1517\/17425255.2014.907274","article-title":"The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]","volume":"10","author":"Filippatos","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110656_bib17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/BF03261927","article-title":"Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors","volume":"51","author":"Golightly","year":"2012","journal-title":"Clin. Pharmacokinet."},{"issue":"15","key":"10.1016\/j.neuropharm.2025.110656_bib18","doi-asserted-by":"crossref","first-page":"8228","DOI":"10.3390\/ijms23158228","article-title":"Social fear affects limbic system neuronal activity and gene expression","volume":"23","author":"Hamann","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110656_bib19","doi-asserted-by":"crossref","first-page":"8060","DOI":"10.1038\/s41598-021-87539-7","article-title":"Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice","volume":"11","author":"Hansen","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110656_bib20","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1161\/HYPERTENSIONAHA.118.11498","article-title":"DPP (dipeptidyl peptidase)-4 inhibition potentiates the vasoconstrictor response to NPY (neuropeptide Y) in humans during renin-angiotensin-aldosterone system inhibition","volume":"72","author":"Hubers","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.neuropharm.2025.110656_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115270","article-title":"Gliptins normalize posttraumatic hippocampal neurogenesis and restore cognitive function after controlled cortical impact on sensorimotor cortex","volume":"165","author":"Hung","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.neuropharm.2025.110656_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120378","article-title":"Linagliptin attenuates thioacetamide-induced hepatic encephalopathy in rats: modulation of C\/EBP-\u03b2 and CX3CL1\/Fractalkine, neuro-inflammation, oxidative stress and behavioral defects","volume":"295","author":"Hussien","year":"2022","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110656_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228750","article-title":"The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation","volume":"15","author":"Ide","year":"2020","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110656_bib24","first-page":"1424","article-title":"Effects of DPP-4 inhibitors on brain natriuretic peptide, neuropeptide Y, glucagon like peptide-1, substance P levels and global longitudinal strain measurements in type 2 diabetes mellitus patients","volume":"5","author":"Kalkan","year":"2022","journal-title":"J. Health Sci. Med."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110656_bib25","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00213-019-05199-y","article-title":"Effects of conditioned social fear on ethanol drinking and vice-versa in male mice","volume":"236","author":"Kornhuber","year":"2019","journal-title":"Psychopharmacology (Berl)."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110656_bib26","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.3390\/ijms22073695","article-title":"Brain region-dependent effects of neuropeptide Y on conditioned social fear and anxiety-like behavior in male mice","volume":"22","author":"Kornhuber","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.neuropharm.2025.110656_bib27","doi-asserted-by":"crossref","first-page":"8220","DOI":"10.3390\/ijms21218220","article-title":"Neuropeptide Y as alternative pharmacotherapy for antidepressant-resistant social fear","volume":"21","author":"Kornhuber","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110656_bib28","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/0269881119862529","article-title":"Neuropeptide Y reduces expression of social fear via simultaneous activation of Y1 and Y2 receptors","volume":"33","author":"Kornhuber","year":"2019","journal-title":"J. Psychopharmacol."},{"issue":"18","key":"10.1016\/j.neuropharm.2025.110656_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221810142","article-title":"Neuropeptide Y reduces social fear in male mice: involvement of Y1 and Y2 receptors in the dorsolateral septum and central amygdala","volume":"22","author":"Kornhuber","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.neuropharm.2025.110656_bib30","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.3390\/ijms21155537","article-title":"Social fear memory requires two stages of protein synthesis in mice","volume":"21","author":"Kornhuber","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110656_bib31","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212573","article-title":"Comorbidity in social anxiety disorder: diagnostic and therapeutic challenges","volume":"8","author":"Koyuncu","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.neuropharm.2025.110656_bib32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.nlm.2013.04.005","article-title":"Role of NPY Y1 receptor on acquisition, consolidation and extinction on contextual fear conditioning: dissociation between anxiety, locomotion and non-emotional memory behavior","volume":"103","author":"Lach","year":"2013","journal-title":"Neurobiol. Learn. Mem."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110656_bib33","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/01616412.2018.1474840","article-title":"Sitagliptin rescues memory deficits in Parkinsonian rats via upregulating BDNF to prevent neuron and dendritic spine loss","volume":"40","author":"Li","year":"2018","journal-title":"Neurol. Res."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110656_bib34","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.3390\/molecules27082478","article-title":"Linagliptin, a selective dipeptidyl peptidase-4 inhibitor, reduces physical and behavioral effects of morphine withdrawal","volume":"27","author":"Listos","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.neuropharm.2025.110656_bib35","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5045182","article-title":"Vildagliptin can alleviate endoplasmic reticulum stress in the liver induced by a high fat diet","author":"Ma","year":"2018","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.neuropharm.2025.110656_bib36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.biopha.2016.10.098","article-title":"Potential involvement of JNK1 repression in the hepatic effect of sitagliptin and metformin in rats subjected to high fat diet and chronic mild distress","volume":"85","author":"Magdy","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.neuropharm.2025.110656_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114238","article-title":"Vildagliptin restores cognitive function and mitigates hippocampal neuronal apoptosis in cisplatin-induced chemo-brain: imperative roles of AMPK\/Akt\/CREB\/BDNF signaling cascades","volume":"159","author":"Mahmoud","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.neuropharm.2025.110656_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174602","article-title":"Saxagliptin ameliorated the depressive-like behavior induced by chronic unpredictable mild stress in rats: impact on incretins and AKT\/PI3K pathway","volume":"912","author":"Nazeem","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110656_bib39","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.3390\/ijms23042388","article-title":"Neuroprotective effects of the DPP4 inhibitor vildagliptin in in vivo and in vitro models of Parkinson's disease","volume":"23","author":"Pariyar","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5983","key":"10.1016\/j.neuropharm.2025.110656_bib40","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1126\/science.1186909","article-title":"Induction of fear extinction with hippocampal-infralimbic BDNF","volume":"328","author":"Peters","year":"2010","journal-title":"Science."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110656_bib41","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00210-020-01838-w","article-title":"Impact of some oral hypoglycemic agents on type 2 diabetes-associated depression and reserpine-induced depression in rats: the role of brain oxidative stress and inflammation","volume":"393","author":"Soliman","year":"2020","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.neuropharm.2025.110656_bib42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.npep.2015.09.007","article-title":"The role of neuropeptide Y in fear conditioning and extinction","volume":"55","author":"Tasan","year":"2016","journal-title":"Neuropeptides"},{"key":"10.1016\/j.neuropharm.2025.110656_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/0471142301.ns0942s63","article-title":"Social fear conditioning as an animal model of social anxiety disorder","author":"Toth","year":"2013","journal-title":"Curr. Protoc. Neurosci."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110656_bib44","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/npp.2011.329","article-title":"Social fear conditioning: a novel and specific animal model to study social anxiety disorder","volume":"37","author":"Toth","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110656_bib45","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/j.1476-5381.2012.01872.x","article-title":"NPY controls fear conditioning and fear extinction by combined action on Y1 and Y2 receptors","volume":"166","author":"Verma","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110656_bib46","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.neuropharm.2015.08.038","article-title":"NPY Y2 receptors in the central amygdala reduce cued but not contextual fear","volume":"99","author":"Verma","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110656_bib47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.brainres.2018.04.031","article-title":"Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced depression model via improving hippocampal neural plasticity","volume":"1694","author":"Weina","year":"2018","journal-title":"Brain Res."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110656_bib48","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1210\/js.2019-00185","article-title":"Dipeptidyl peptidase 4 inhibition increases postprandial norepinephrine via substance P (NK1 receptor) during RAAS inhibition","volume":"3","author":"Wilson","year":"2019","journal-title":"J. Endocr. Soc."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110656_bib49","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/nu15010038","article-title":"Glucagon-like peptide 1 receptor activation inhibits microglial pyroptosis via promoting mitophagy to alleviate depression-like behaviors in diabetic mice","volume":"15","author":"Yang","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.neuropharm.2025.110656_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171271","article-title":"Tirzepatide shows neuroprotective effects via regulating brain glucose metabolism in APP\/PS1 mice","volume":"179","author":"Yang","year":"2024","journal-title":"Peptides"},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110656_bib51","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3390\/cells12101355","article-title":"Development of comorbid depression after social fear conditioning in mice and its effects on brain sphingolipid metabolism","volume":"12","author":"Zoicas","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.neuropharm.2025.110656_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-025-02146-8","article-title":"Sitagliptin as a therapeutic approach for social anxiety disorder: the role of DPP4 and NPY in modulating social fear and comorbid depressive-like behavior in mice","author":"Zoicas","year":"2025","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110656_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177556","article-title":"Dipeptidyl peptidase-4 inhibitors enhance memory retention via neuropeptide Y","volume":"996","author":"Zoicas","year":"2025","journal-title":"Eur. J. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825003648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825003648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:15:41Z","timestamp":1780028141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825003648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":53,"alternative-id":["S0028390825003648"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110656","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early treatment with vildagliptin and linagliptin reduces social fear and prevents the onset of comorbid depression in a mouse model of social anxiety disorder","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110656","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110656"}}